A Phase 3 interventional study of AD-227A and AD-227B in Essential Hypertension, sponsored by Addpharma Inc.. Recruiting at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2025-02-04.
Sponsored by Addpharma Inc. (part of Yuhan Corporation) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Essential Hypertension by Yuhan Corporation — 2 open to participants now, 4 under way, 2 of them phase 3. Essential Hypertension · Yuhan Corporation.
Among the 10 studies in Essential Hypertension by Yuhan Corporation, this one is one of 4 that started in 2024, is one of 5 in phase 3, and was the 8th registered.
481 studies on the registry are indexed under Essential Hypertension; 77 are open to participants now.
Browse Essential Hypertension studies →2 of the 10 studies in Essential Hypertension by Yuhan Corporation are open now, in 1 country. Recruiting first, the newest first:
Addpharma Inc. · Sites in Korea, Republic of
Ages 19+
By country, each count listing its studies:
Of the 45 Essential Hypertension studies recruiting now, 17 (38%) set no upper age limit and 20 (44%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2020; this study’s year is marked. 4 started in 2024.
This study's planned enrollment of 251 is above the median of 144 across 408 interventional studies indexed under Essential Hypertension.
Median enrollment 221 across the 9 interventional studies, 1,219 across the 1 observational. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Addpharma Inc., one of the names counted as Yuhan Corporation. Under that name alone:
Addpharma Inc. is the lead sponsor of 58 studies on the registry; 25 are open to participants now.
1 of the studies in Essential Hypertension by Yuhan Corporation that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06282549Yuhan CorporationStudy to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients with Essential Hypertension | 2027-03-31 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Essential Hypertension by Yuhan Corporation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of co-administration of AD-227A and AD-227B in patients with essential hypertension
Essential Hypertension
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
AD-227A + AD-227B + Placebo of AD-227C
Drug: AD-227A · Drug: AD-227B · Drug: Placebo of AD-227C
AD-227A + Placebo of AD-227B + Placebo of AD-227C
Drug: AD-227A · Drug: Placebo of AD-227B · Drug: Placebo of AD-227C
AD-227A + Placebo of AD-227B + AD-227C
Drug: AD-227A · Drug: AD-227C · Drug: Placebo of AD-227B
Per Oral, 1 Tablet, Once a day for 8 weeks
Per Oral, 1 Tablet, Once a day for 8 weeks
Per Oral, 1 Tablet, Once a day for 8 weeks
Per Oral, 1 Tablet, Once a day for 8 weeks
Per Oral, 1 Tablet, Once a day for 8 weeks
Change in MSSBP
Change from Baseline in Mean Sitting Systolic Blood Pressure
Time frame: Baseline to Week8
Started Jul 2024 (actual). Primary completion is estimated for Sep 2025, 14 months after the start.
Of 45 industry-sponsored phase 3 interventional studies under Essential Hypertension, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 24. This study's planned 14 months is below that.
Counting every sponsor, half of 47 studies reached it within 17 months; a quarter within 11 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.